| Market Capitalization (Millions $) |
54 |
| Shares
Outstanding (Millions) |
60 |
| Employees |
74 |
| Revenues (TTM) (Millions $) |
10 |
| Net Income (TTM) (Millions $) |
-86 |
| Cash Flow (TTM) (Millions $) |
20 |
| Capital Exp. (TTM) (Millions $) |
0 |
Kronos Bio Inc
Kronos Bio Inc is a US-based clinical-stage biopharmaceutical company that was founded in 201 The company is engaged in the research and development of small molecule drugs that can target historically difficult to drug protein targets. It aims to develop novel drug therapies for the treatment of various oncology and immunology diseases. The company is headquartered in New York City and has a team of dedicated scientists and professionals committed to discovering new therapeutics.
The companyes founders, Norbert Bischofberger and Angela Koehler, possess extensive experience in drug discovery and development, including serving as executives at Gilead Sciences, one of the largest biopharmaceutical companies in the world. Kronos Bio utilizes its proprietary chemistry technology, which combines innovative medicinal chemistry with modern computational biology, to discover and develop highly specific and efficient small molecule drugs against historically undruggable targets.
Kronos Bioes lead product candidate, entospletinib (formerly LSF-121), is a highly selective and potent inhibitor of spleen tyrosine kinase (SYK). This drug has been developed for the treatment of patients with acute myeloid leukemia (AML) and non-Hodgkines lymphoma (NHL). Currently, the company is conducting multiple clinical trials for entospletinib in patients with AML and NHL.
Aside from entospletinib, the company also has several other promising drug candidates in its pipeline. KB-0742 is a highly selective inhibitor of cyclin-dependent kinase 9 (CDK9), which is being developed for the treatment of various hematologic malignancies and solid tumors. KB-0742 has demonstrated higher specificity and potency than currently available CDK9 inhibitors, which could lead to fewer side effects and better clinical outcomes for patients.
Kronos Bio is committed to transforming the way we treat cancer and other devastating diseases. With its innovative approach to drug discovery and development, the company is uniquely positioned to develop highly targeted and effective drug therapies against historically undruggable targets. The company has received significant interest and funding from venture capitalists, including $105 million in a series A funding round in 2019. Overall, Kronos Bio has the potential to make a significant impact in the biopharmaceutical industry and improve patient outcomes.
Company Address: 1300 So. El Camino Real San Mateo 94402 CA
Company Phone Number: 781-5200 Stock Exchange / Ticker: NASDAQ KRON
|
5.86% 